PTGS2 and breast cancer: Since the upregulation of COX-2 has been implicated in cancer therapy resistance [8], the latter result raised the possibility that DEA decreased its own anti-neoplastic effects in the 4T1 cell line, thereby creating the difference between the two BC cell lines in response to DEA treatment.